TARA presented a poster in collaboration with GlaxoSmithKline at the 57th Society of Toxicology (SOT) Annual Meeting. At SOT, toxicologists from around the world meet to share the latest research and advancements in the field. Biowire™ II enables precision cardiology efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities. Come see our poster during the Cardiovascular Toxicology: In Vitro Systems session on Monday, March 12: (Poster P185, Abstract #1145) - "Biowire II-Matured Human-Engineered Cardiac Tissues Have Adult-Like Responses to Inotropic Agents."
TARA Presents at SOT Annual Meeting 2018
As a result, currently 8 out of 9 drugs tested for cardiotoxicity fail in clinical trials, after spending significant time.